SARS

March 18, 2021

Study to assess allergic reactions to COVID vaccines

Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna.

By Bill Snyder
June 29, 2017

Team investigates antiviral that inhibits SARS, MERS

A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine.

By Leigh MacMillan
February 24, 2015

Contributors to coronavirus ‘fitness’

Understanding the role that host membrane modification plays in coronavirus replication is essential for developing novel approaches to block the viruses that cause SARS and MERS.

By Leigh MacMillan
September 12, 2013

‘Proofreader’ key to coronavirus growth

A coronavirus protein is required for replication of the viral genome and may be a good treatment target for SARS and other diseases caused by coronaviruses.

By Leigh MacMillan
syringe
November 12, 2012

UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses

Collaborating researchers at the University of North Carolina and Vanderbilt University have found that accelerating the rate of mutations in the coronavirus responsible for deadly severe acute respiratory syndrome (SARS) cripples the virus’s ability to cause disease in animals.

By VUMC News and Communications